Categories
Uncategorized

Oklahoma reports 787 new COVID-19 cases since Friday; total provisional death count rises by 21 – KOCO Oklahoma City

Sorry, Readability was unable to parse this page for content.

Categories
Uncategorized

COVID-19 Statistics | April 19, 2021 – Lost Coast Outpost

One Death, 34 New Cases Reported Since Friday 

A Humboldt County resident in their 70s has died with COVID-19, and 34 additional cases of the virus have been reported since Friday. The total number of county residents who have tested positive for COVID-19 now stands at 3,621. 

This marks the 38th death related to COVID-19 in Humboldt County. Public Health and Emergency Operations Center staff share their sympathies with the person’s friends, caregivers and family. 

Temporary Fix Developed for ‘My Turn’ Issue 

Many COVID-19 vaccination appointments are available locally this week, and Humboldt County residents are encouraged to sign up now at MyTurn.ca.gov. Don’t wait to be contacted. Though My Turn is designed to provide notifications of upcoming openings, the best way to find an available appointment is to check the website regularly. 

The state’s My Turn portal has put in place geofencing that restricts people who live more than 40 miles from a clinic site from viewing available appointments, which has meant that residents of much of Southern Humboldt have been unable to see or schedule appointments. This limitation has affected many, if not all, rural California counties, and local Public Health officials are addressing it directly with the state. 

Until the state resolves the issue, when prompted to “Enter your address or zip code,” county residents should enter only “Humboldt County” on the “Let’s Find an Appointment” page of the My Turn website, the third page of the appointment scheduler. This means residents will input “Humboldt County” in two different places. 

Anyone with questions can call the state’s COVID-19 Hotline at 1-833-422-4255 or call the Humboldt County Joint Information Center at 707-441-5000. 

There are alternatives to My Turn, as well. Walk-in vaccination hours are scheduled for 6 to 7 p.m. Wednesday through Sunday at the Arcata Community Center, which is located at 321 Dr. Martin Luther King, Pkwy. Also, the federal government supports scheduling vaccinations at local pharmacies through https://vaccinefinder.org/

Johnson & Johnson Vaccine Remains ‘Paused’ 

Administration of the Johnson & Johnson vaccine is still on hold. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices will meet to review cases of a rare but serious blood clot that developed in six women after they received the Johnson & Johnson vaccine. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he anticipates a decision about whether to continue the pause will be made when the committee meets Friday.
 

View the Humboldt County Data Dashboard online at humboldtgov.org/dashboard, or go to humboldtgov.org/DashboardArchives to download today’s data. 

For the most recent COVID-19 information, visit cdc.gov or cdph.ca.gov. Local information is available at humboldtgov.org or by contacting covidinfo@co.humboldt.ca.us or calling 707-441-5000. 

Some Safeway, CVS Pharmacy, Rite Aid, Walgreen’s and Walmart locations are offering COVID-19 vaccination appointments. Learn who is eligible for vaccination and see if there are appointments available at one of these locations by clicking on the links below.

Safeway: mhealthappointments.com/covidappt
CVS Pharmacy: cvs.com/immunizations/covid-19-vaccine?icid=cvs-home-hero1-link2-coronavirus-vaccine
Rite Aid: https://www.riteaid.com/covid-19
Walgreen’s: walgreens.com/findcare/vaccination/covid-19
Walmart: walmart.com/cp/1228302 

Sign up for COVID-19 vaccination: MyTurn.ca.gov
Local COVID-19 vaccine information: humboldtgov.org/VaccineInfo
Humboldt County COVID-19 Data Dashboard: humboldtgov.org/Dashboard
Follow us on Facebook: @HumCoCOVID19
Instagram: @HumCoCOVID19
Twitter: @HumCoCOVID19
Humboldt Health Alert: humboldtgov.org/HumboldtHealthAlert  

###

 

Categories
Uncategorized

DOST OK with clinical trial to test ivermectin vs COVID-19 – ABS-CBN News

Sorry, Readability was unable to parse this page for content.

Categories
Uncategorized

World can bring pandemic under control within months, WHO chief says – KSL.com

Sorry, Readability was unable to parse this page for content.

Categories
Uncategorized

One country has almost entirely wiped out COVID-19 | TheHill – The Hill

One country has almost entirely wiped out COVID-19, and it isn’t the United States.

According to a new study, Israel, which has the most expansive vaccination program and rates in the world, has “pretty much eradicated COVID-19 […] at least for the time being,” according to a tweet from the study’s co-author, Eran Segal.


Our country is in a historic fight against the Coronavirus. Add Changing America to your Facebook or Twitter feed to stay on top of the news.


The paper, published Monday in the journal Nature, found that the mass vaccinations decimated case numbers and deaths. Compared to Israel’s peak in January, the scientists found that following the mass vaccinations there was a 98 percent drop in cases, 93 percent fewer critically ill patients, and 87 percent fewer deaths.

Israel has vaccinated 61.7 percent of its 9.3 million citizens. 

The promising numbers have resulted in the government relaxing mask mandates and reopening schools and universities. 

However, experts are still cautious. Territories in the West Bank and Gaza have seen a much slower vaccination rollout, and the rise in new variants of the coronavirus have prompted questions about how long vaccinations will be effective for and against what variants.

Moderna announced this month that it is working on a booster shot to better protect against coronavirus variants that should be available in late 2021, and Pfizer said a booster shot is likely to be needed within 12 months.


WHAT YOU NEED TO KNOW ABOUT CORONAVIRUS RIGHT NOW

FEWER THAN 6,000 PEOPLE HAVE GOTTEN COVID-19 AFTER BEING FULLY VACCINATED, SAYS CDC

IVANKA TRUMP’S VACCINATION SPARKS BACKLASH AMONG HER FANS

MODERNA SAYS ITS BOOSTER SHOT AGAINST COVID-19 COULD BE AVAILABLE BY THE FALL

US CALLS TO SUSPEND USE OF J&J VACCINE AFTER BLOOD CLOTTING PROBLEMS

NEW STUDY SAYS MODERNA VACCINE LEADS TO MORE SIDE EFFECTS THAN PFIZER VACCINE

Categories
Uncategorized

COVID-19 damages brain without infecting it, study suggests – CIDRAP

Although SARS-CoV-2 probably does not infect the brain, it can damage it significantly, a new study of autopsies of 41 COVID-19 patients finds.

Researchers at Columbia University say that they found no signs of virus inside the patients’ brain cells but saw many brain abnormalities that could explain the confusion and delirium seen in some patients with severe coronavirus and the lingering “brain fog” in those with mild disease.

The study, which the authors called the largest COVID-19 brain autopsy report thus far, involved analysis of samples from autopsies conducted from March to June 2020 and was published late last week in Brain. The findings, they said, suggest that the inflammation triggered by the coronavirus in other parts of the body or in the brain’s blood vessels may have caused the neurologic abnormalities seen in the autopsies.

Lack of oxygen, cell death

The brain damage consisted of areas starved of oxygen, many of them hemorrhagic, which the researchers said were likely caused by blood clots that temporarily blocked the flow of oxygen. Many activated microglia, or immune cells in the brain that can be activated by pathogens, were also identified.

“We found clusters of microglia attacking neurons, a process called ‘neuronophagia,'” co-senior author Peter Canoll, MD, PhD, said in a Columbia University press release.

Because no virus was observed in the brain, he said that the microglia may have been activated by inflammatory cytokines, which are tied to coronavirus infection. “At the same time, hypoxia [reduced oxygen from COVID-19] can induce the expression of ‘eat me’ signals on the surface of neurons, making hypoxic neurons more vulnerable to activated microglia.”

Most activated microglia were found in the lower brain stem, which is responsible for heart and breathing rhythms and levels of consciousness, and in the hippocampus, which is involved in mood and memory.

“We know the microglia activity will lead to loss of neurons, and that loss is permanent,” co-senior author James Goldman, MD, PhD, said in the release. “Is there enough loss of neurons in the hippocampus to cause memory problems? Or in other parts of the brain that help direct our attention? It’s possible, but we really don’t know at this point.”

Implications for survivors

Of the 41 patients, 59% required intensive care, and about half required intubation. Hospital-related complications were common, including deep vein thrombosis or pulmonary embolism (20%), acute kidney injury necessitating dialysis (17%), and bacteremia (24%). About 20% of patients died within 24 hours of hospitalization, while 27% died 4 or more weeks after admission.

All of the patients, who were 74 years on average, had signs of virus-related lung damage. Sixty-six percent of the patients were men, and 83% were Hispanic/Latino.

The authors said that future studies should aim to determine whether some COVID-19 survivors have any of these neurologic abnormalities and whether they lead to chronic neurologic deficits.

“In light of the brainstem and hippocampal distribution of microglial activation, the latter of which has been linked to virus-induced cognitive deficits, it is notable that some COVID-19 survivors develop neuropsychiatric symptoms, including memory disturbances, somnolence, fatigue and insomnia, and that similar symptoms are reported in both the acute and recovery phases,” they wrote.

“This study included only patients who were severely ill and died. These changes may not be seen in patients with mild illness.”

Categories
Uncategorized

Physical inactivity tied to higher COVID-19 risk; new trial attempts to reinfect virus survivors – Yahoo News

By Nancy Lapid

(Reuters) -The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Physical inactivity tied to higher COVID-19 risks

Patients with COVID-19 who have been consistently physically inactive have a significantly higher risk of severe outcomes than patients who were getting at least some exercise or regularly met physical activity guidelines prior to the illness, researchers found. Among the 48,440 patients in their study, 14.4% were consistently inactive in the two years before their COVID-19 diagnosis, 79.1% had some activity, and 6.4% consistently met recommended physical activity guidelines of at least 150 minutes per week. Compared with those who consistently met activity guidelines, people who were consistently inactive were more than twice as likely to be hospitalized and to die from the virus, according to a report in the British Journal of Sports Medicine. Consistently inactive patients also had worse outcomes than patients who got some exercise without meeting the guideline-recommended minimum. “It is well known that immune function improves with regular physical activity, and those who are regularly active have a lower incidence, intensity of symptoms and death from viral infections,” said coauthor Dr. Robert Sallis of the Kaiser Permanente Fontana Medical Center in California. “Regular physical activity is associated with improvements in lung capacity and cardiovascular and muscular functioning that may serve to lessen the negative impacts of COVID-19 if it is contracted,” he added. (https://bit.ly/3wVU8wx)

New trial attempts to reinfect COVID-19 survivors

British scientists on Monday launched a trial that will deliberately re-expose COVID-19 survivors to the coronavirus to examine their immune responses and see if they become reinfected. The information from the so-called challenge trial “will allow us to design better vaccines and treatments, and also to understand if people are protected after having COVID, and for how long,” said study leader Helen McShane of the University of Oxford. The first stage of the trial will seek to establish the lowest dose of the coronavirus needed in order for it to start replicating in about 50% of the volunteers, while producing few to no symptoms. A second phase will infect different volunteers with that standard dose. Everyone will quarantine for at least 17 days, and anyone who develops symptoms will receive a monoclonal antibody treatment manufactured by Regeneron Pharmaceuticals Inc. Researchers leading a separate UK study are administering the virus to volunteers who were not previously infected. “These challenge studies… will significantly improve our understanding of the dynamics of virus infection and of the immune response, as well as provide valuable information to help with the on-going design of vaccines and the development of anti-viral therapies,” Lawrence Young, a virologist at Warwick Medical School in the UK, said in a statement. (https://reut.rs/2RCBVnl)

Low interferon levels drive weak response to the virus

People who become critically ill with COVID-19 appear to have lower-than-average levels of inflammatory proteins called interferons, and a new study helps explain why low interferon levels would matter. Researchers identified 65 genes that are triggered into action by interferons – including some that inhibit the ability of the virus to enter cells and others that suppress manufacture of the virus’ genetic material or inhibit its ability to assemble itself – part of the virus replication process. Eight of the “interferon-stimulated genes” act not only against the SARS-CoV-2 virus that causes COVID-19 but also against the SARS-CoV-1 virus that caused the 2003 SARS outbreak, the researchers reported in Molecular Cell. “The interferon response to SARS-CoV-2 infection relies on a limited subset of … genes that govern a diverse set of cellular functions,” the researchers said. “We wanted to gain a better understanding of the cellular response to SARS-CoV-2, including what drives a strong or weak response to infection,” coauthor Sumit Chanda of Sanford Burnham Prebys in La Jolla, California said in a statement. “We’ve gained new insights into how the virus exploits the human cells it invades, but we are still searching for its Achilles heel.” (https://bit.ly/2P8gV7i)

Open https://tmsnrt.rs/3c7R3Bl in an external browser for a Reuters graphic on vaccines in development.

(Reporting by Nancy Lapid, Lisa Rapaport and Alistair Smout; Editing by Bill Berkrot)

Categories
Uncategorized

Can you spread the coronavirus if youre vaccinated? Post reporters answer your questions. – The Washington Post

Please enable cookies on your web browser in order to continue.

The new European data protection law requires us to inform you of the following before you use our website:

We use cookies and other technologies to customize your experience, perform analytics and deliver personalized advertising on our sites, apps and newsletters and across the Internet based on your interests. By clicking “I agree” below, you consent to the use by us and our third-party partners of cookies and data gathered from your use of our platforms. See our Privacy Policy and Third Party Partners to learn more about the use of data and your rights. You also agree to our Terms of Service.

Categories
Uncategorized

Young, healthy adults will be deliberately reinfected with COVID-19 to boost vaccine development – MarketWatch

Healthy, young volunteers who have previously had COVID-19 will be deliberately exposed to coronavirus for a second time to see how the immune system responds, as part of a new U.K. study.

Researchers at the University of Oxford on Monday launched the “human challenge” trial to investigate what happens when volunteers who have recovered from the coronavirus disease are then reinfected with the virus a second time.

The study, which is funded by the Wellcome Trust, is expected to start in the next few weeks after receiving ethics approval, and could help accelerate the development of new treatments and vaccines against the disease.

Human challenge studies have played a crucial role in the development of treatments for a number of diseases, including malaria, typhoid, cholera and flu.

Read: Only 50 people are known to have contracted COVID-19 more than once — but new strains have medical experts on high alert

“A challenge study allows us to make these measurements very precisely because we know exactly when someone is infected,” said Helen McShane, professor of vaccinology at the department of pediatrics at the University of Oxford and chief investigator on the study.

“The information from this work will allow us to design better vaccines and treatments, and also to understand if people are protected after having COVID, and for how long,” McShane said.

Read: COVID-19 infection likely to provide immunity for at least 5 months, but people may still transmit virus, study finds

The first stage of the trial will involve up to 64 volunteers aged 18-30 who have previously been naturally infected with COVID-19. It will look to establish the lowest dose of virus that can take hold and start replicating in about 50% of participants, while producing few to no symptoms.

Volunteers will be monitored in a safe, controlled environment while quarantined in a specially designed hospital suite for a minimum of 17 days. Anyone who develops coronavirus symptoms will be given Regeneron
REGN,
-0.58%

monoclonal antibody treatment.

Once the standard dose is established, it will be used to infect different volunteers in the second stage of the trial, which is due to start in the summer. The full length of the study will be 12 months, including a minimum of eight follow-up appointments after volunteers have been discharged.

Read: Young, healthy adults will be paid £4,500 to be deliberately infected with COVID-19 in new trial

The new study is different to a parallel one led by Imperial College London, which was announced in February, and will expose up to 90 carefully selected healthy adult volunteers to coronavirus to help researchers understand how the virus infects people and how it is transmitted.

It comes as almost 10 million people in the U.K. have now received their second dose of the COVID-19 vaccine, according to the latest government figures.

Three vaccines are currently in use in the U.K.: the one jointly developed by German biotech BioNTech
BNTX,
-1.36%

and U.S. drug company Pfizer
PFE,
+0.93%

; the one produced by drug company AstraZeneca with the University of Oxford; and the shot from biotech Moderna
MRNA,
-5.21%
.

Last week, Moderna said it would deliver fewer than expected COVID-19 vaccines to the U.K., Canada and other countries, following a shortfall in production in its European supply chain. 

Categories
Uncategorized

Moderna’s effort to develop an HIV vaccine is a ‘different ballgame’: HIV Researcher – Seeking Alpha

Sorry, Readability was unable to parse this page for content.